Ionis Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Ionis Pharmaceuticals is Brett Monia, benoemd in Jan2020, heeft een ambtstermijn van 4.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.50M, bestaande uit 7.7% salaris en 92.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde MX$ 116.59M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 8.5 jaar.

Belangrijke informatie

Brett Monia

Algemeen directeur

US$12.5m

Totale compensatie

Percentage CEO-salaris	7.7%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	8.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Brett Monia's beloning veranderd ten opzichte van Ionis Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$359m
Jun 30 2024	n/a	n/a	-US$366m
Mar 31 2024	n/a	n/a	-US$385m
Dec 31 2023	US$13m	US$961k	-US$366m
Sep 30 2023	n/a	n/a	-US$409m
Jun 30 2023	n/a	n/a	-US$309m
Mar 31 2023	n/a	n/a	-US$329m
Dec 31 2022	US$7m	US$825k	-US$270m
Sep 30 2022	n/a	n/a	US$7m
Jun 30 2022	n/a	n/a	-US$28m
Mar 31 2022	n/a	n/a	-US$4m
Dec 31 2021	US$13m	US$800k	-US$29m
Sep 30 2021	n/a	n/a	-US$608m
Jun 30 2021	n/a	n/a	-US$550m
Mar 31 2021	n/a	n/a	-US$495m
Dec 31 2020	US$11m	US$700k	-US$444m
Sep 30 2020	n/a	n/a	US$94m
Jun 30 2020	n/a	n/a	US$145m
Mar 31 2020	n/a	n/a	US$169m
Dec 31 2019	US$7m	US$528k	US$281m
Sep 30 2019	n/a	n/a	US$433m
Jun 30 2019	n/a	n/a	US$402m
Mar 31 2019	n/a	n/a	US$366m
Dec 31 2018	US$4m	US$508k	US$277m
Sep 30 2018	n/a	n/a	-US$41m
Jun 30 2018	n/a	n/a	-US$38m
Mar 31 2018	n/a	n/a	US$9m
Dec 31 2017	US$2m	US$443k	US$19m

Compensatie versus markt: De totale vergoeding ($USD 12.50M ) Brett } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 2.41M ).

Compensatie versus inkomsten: De vergoeding van Brett is gestegen terwijl het bedrijf verliesgevend is.

CEO

Brett Monia (63 yo)

4.8yrs

Tenure

US$12,500,023

Compensatie

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Brett Monia	Founder	4.8yrs	US$12.50m	0.11% MX$ 116.6m
Elizabeth Hougen	Executive VP of Finance & CFO	11.8yrs	US$2.89m	0.059% MX$ 64.7m
B. Parshall	Director	6.8yrs	US$538.04k	0.055% MX$ 60.8m
Richard Geary	Executive VP & Chief Development Officer	16.3yrs	US$2.56m	0.054% MX$ 59.1m
Eric Swayze	Executive Vice President of Research	4.8yrs	US$2.56m	0.021% MX$ 23.6m
Darren Gonzales	Chief Accounting Officer & Senior VP	4.8yrs	geen gegevens	geen gegevens
C. Bennett	Executive VP & Chief Scientific Officer	4.8yrs	US$958.87k	0.050% MX$ 55.5m
D. Walke	Senior Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Patrick O'Neil	Executive VP	11.8yrs	US$3.92m	0.031% MX$ 34.0m
Hayley Soffer	Vice President of Corporate Communications	less than a year	geen gegevens	geen gegevens
Shannon Devers	Senior Vice President of Human Resources	4.8yrs	geen gegevens	0.0050% MX$ 5.5m
Stanley Crooke	Scientific Advisor	3.4yrs	US$2.28m	geen gegevens

4.8yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IONS * wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Brett Monia	Founder	5.7yrs	US$12.50m	0.11% MX$ 116.6m
B. Parshall	Director	24.2yrs	US$538.04k	0.055% MX$ 60.8m
Joan Herman	Independent Director	5.4yrs	US$540.04k	0.027% MX$ 29.3m
Joseph Klein	Independent Director	18.9yrs	US$542.04k	0.010% MX$ 11.5m
Joseph Wender	Lead Independent Director	30.8yrs	US$598.04k	0.084% MX$ 92.5m
Michael Hayden	Independent Director	6.2yrs	US$528.04k	0.020% MX$ 22.4m
Spencer Berthelsen	Independent Director	22.5yrs	US$548.04k	0.096% MX$ 105.9m
Joseph Loscalzo	Independent Chairman of the Board	10.8yrs	US$568.04k	0.020% MX$ 22.5m
Allene Diaz	Independent Director	3.4yrs	US$530.04k	0.010% MX$ 10.9m
Michael Yang	Independent Director	less than a year	US$363.05k	geen gegevens

8.5yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IONS * wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.5 jaar).

Ionis Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Recent updates

Insufficient new directors

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.45 loss per share (vs US$0.60 loss in 2Q 2023)

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Insufficient new directors

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen

Frederick Muto Retires from Ionis Pharmaceuticals, Inc., Effective July 15, 2022

Insufficient new directors

Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Pharmaceuticals, Inc. Announces Results from the Phase 3 Valor Study and Its Open-Label Extension of tofersen

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur